Clinical Research Directory

Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

Sponsor: Peking Union Medical College

Summary

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Official title: Real-World Evaluation of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa

Key Details

Conditions

Interventions

Locations (1)